Use of Ebola Vaccines — Worldwide, 2021–2023
Authors:
- Ruth KallayRKRuth Kallay
- Reena H. DoshiRDReena H. Doshi
- Pierre MuhozaPMPierre Muhoza
- Mary J. ChoiMCMary J. Choi
- Anaïs LegandALAnaïs Legand
- Emma Aberle-GrasseEAEmma Aberle-Grasse
- Aminata BagayokoABAminata Bagayoko
- Terri B. HydeTHTerri B. Hyde
- Pierre FormentyPFPierre Formenty
- Alejandro CostaACAlejandro Costa
Open Access
- 25 April 2024
- journal article
- research article
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 73 (16) , 360-364
Abstract
This report describes repurposing Ebola vaccines in the absence of large outbreaks.Keywords
This publication has 4 references indexed in Scilit:
- Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the CongoThe Lancet Infectious Diseases, 2024
- Targeted preventive vaccination campaigns to reduce Ebola outbreaks: An individual-based modeling studyVaccine, 2022
- Vaccination of contacts of Ebola virus disease survivors to prevent further transmissionThe Lancet Global Health, 2020
- Meeting of the Strategic Advisory Group of Experts on Immunization, April 2012-Conclusions and Recommendations2014